MTK2 Antibody

What is MTK2 antibody and what target does it recognize?

MTK2 is a monoclonal antibody that specifically recognizes the human c-kit receptor (CD117), a 140 kDa type III receptor tyrosine kinase. It was originally obtained by immunizing mice with a human megakaryoblastic leukemia cell line, M-MOK . Unlike its counterpart MTK1, MTK2 does not inhibit stem cell factor (SCF)-induced cell proliferation, suggesting it targets a different epitope on the c-kit receptor that's not involved in ligand binding or downstream signaling .

How does MTK2 antibody differ from MTK1 antibody?

While both MTK1 and MTK2 recognize the human c-kit receptor, they exhibit distinct immunological, biochemical, and biological behaviors:

• Both allow visualization of the 140 kDa c-kit protein by Western blot analysis, but MTK1 detects only positive bands under non-reducing conditions for SDS-PAGE, suggesting it recognizes a conformation-dependent epitope

• MTK1 partially inhibits SCF-induced proliferation of M-MOK cells, whereas MTK2 is without inhibitory effect

• MTK1 inhibits bone marrow-derived colony-forming unit granulocyte/macrophage (CFU-GM) formed by GM-CSF and SCF, while MTK2 doesn't show this activity

• These differences indicate they bind to different functional domains of the c-kit receptor

What are the common applications for MTK2 antibody in research?

MTK2 antibody is valuable for multiple research applications:

• Western blot analysis for detecting c-kit protein expression

• Immunohistochemistry/immunofluorescence for visualizing c-kit in tissues

• Flow cytometry for quantitative analysis of cell surface c-kit expression

• Cell sorting applications to isolate c-kit-positive cell populations

• Studies of hematopoietic stem cells alongside other markers like CD34

Because it doesn't inhibit c-kit signaling (unlike MTK1), MTK2 is particularly useful for detection applications where maintaining receptor functionality is important.

How should I optimize Western blot conditions for MTK2 antibody?

For optimal Western blot results with MTK2 antibody:

MTK2 should clearly visualize the 140 kDa c-kit protein on your blot . If working with glycosylated forms of c-kit, you may observe higher molecular weight bands.

What validation methods should I use to confirm MTK2 antibody specificity?

Comprehensive validation of MTK2 antibody should include multiple approaches:

• Genetic validation: Use CRISPR/Cas9 genomic editing to knockout c-kit in positive cell lines

• Transfection controls: Compare Balb/3T3 cells transfected with human c-kit cDNA versus parent cells

• Multiple assay concordance: Verify consistent detection pattern across Western blot, IHC, flow cytometry

• Orthogonal validation: Use a different method (such as PCR) to confirm c-kit expression levels

• Recombinant expression validation: Test against cells overexpressing c-kit

• Peptide competition: If the epitope is known, perform blocking experiments

• Cross-comparison: Compare results with other validated c-kit antibodies targeting different epitopes

Following the "five pillars of antibody validation" approach can significantly improve confidence in your results . Document these validation steps thoroughly in your methods section.

What sample preparation methods work best for immunohistochemistry with MTK2 antibody?

For effective immunohistochemistry with MTK2 antibody:

When evaluating c-kit staining patterns, remember that normal expression includes mast cells, melanocytes, interstitial cells of Cajal, and certain hematopoietic progenitor cells .

What are common causes of high background when using MTK2 antibody?

High background with MTK2 antibody can stem from several sources:

Systematic testing of these variables will help identify the specific cause in your experimental system.

Why might I see discrepancies between MTK2 and other c-kit antibodies?

Discrepancies between MTK2 and other c-kit antibodies may result from:

• Epitope differences: MTK2 recognizes a specific epitope that might be masked in certain c-kit conformations or post-translational modifications

• Isoform specificity: Human c-kit has multiple splice variants, and different antibodies may preferentially detect specific isoforms

• Sensitivity differences: Antibodies vary in binding affinity and detection threshold

• Protocol compatibility: Some antibodies perform better in certain applications (Western vs. IHC vs. flow cytometry)

• Sample preparation effects: Fixation, embedding, or extraction methods may differentially affect epitope accessibility

• Cross-reactivity variations: Different antibodies may have different species cross-reactivity profiles

To resolve discrepancies, use multiple detection methods and consider antibody pairs recognizing different epitopes as mutual validation.

How can I optimize MTK2 antibody concentration for my specific application?

Optimal MTK2 antibody concentration determination requires systematic titration:

Create a titration curve plotting antibody concentration versus signal intensity to identify the optimal range. Different sample types (cell lines versus primary samples, different tissue fixation methods) may require different concentrations.

How can I use MTK2 antibody in combination with phospho-specific c-kit antibodies?

To study c-kit signaling dynamics:

• Use MTK2 to detect total c-kit while phospho-specific antibodies monitor activation status

• Design time-course experiments where cells are stimulated with SCF (0-60 minutes)

• Analyze samples by Western blot, flow cytometry, or immunofluorescence

• For multiplexed approaches, ensure MTK2 and phospho-antibodies are from different host species

• Calculate the ratio of phosphorylated to total c-kit over time, normalizing to account for receptor internalization

• Compare signaling kinetics between normal and mutated c-kit variants or after drug treatments

This approach provides detailed activation profiles and is particularly valuable for studying c-kit mutations in diseases like gastrointestinal stromal tumors or acute myeloid leukemia.

What considerations are important when using MTK2 for isolating c-kit-positive cells?

When using MTK2 antibody to isolate c-kit-positive stem/progenitor cells:

For magnetic separation (MACS), biotinylated secondary antibodies with anti-biotin microbeads often provide good results. For FACS, use appropriate gating strategies to exclude dead cells and doublets.

How can I perform immunoprecipitation with MTK2 antibody for mass spectrometry analysis?

For immunoprecipitation with MTK2 followed by mass spectrometry:

• Cell lysis: Use a gentle non-denaturing lysis buffer (1% NP-40 or CHAPS-based) to preserve protein-protein interactions

• Pre-clearing: Remove non-specific binding proteins with protein G beads (1 hour, 4°C)

• Immunoprecipitation: Incubate cleared lysate with MTK2 antibody (5-10 μg) overnight at 4°C

• Capture: Add protein G beads for 2-4 hours at 4°C

• Washing: Perform stringent washes (at least 4-5) to remove non-specific proteins

• Elution: Use gentle elution with peptide competition or more stringent SDS-based buffers

• Sample preparation: Process samples according to your mass spectrometry facility's requirements

• Data analysis: Search for c-kit and interacting partners; validate novel interactions by orthogonal methods

This approach can identify c-kit binding partners and post-translational modifications, providing insights into c-kit signaling networks .

How can I convert MTK2 hybridoma to recombinant antibody format?

Converting MTK2 from hybridoma to recombinant format involves:

• Sequence determination: Extract RNA from hybridoma, perform RT-PCR with degenerate primers or use whole transcriptome shotgun sequencing to identify antibody variable regions

• Sequence verification: Confirm antibody classification (likely IgG with kappa light chain)

• Vector design: Clone sequences into expression vectors with appropriate leader peptides and constant regions

• Expression system: Use HEK293 or CHO cells for mammalian expression, or consider other systems

• Purification: Use protein A/G affinity chromatography for initial capture

• Validation: Compare recombinant antibody performance to the original hybridoma product across applications

Recombinant antibodies offer advantages of consistency, renewable supply, and engineering potential. Studies show recombinant antibodies generally outperform traditional monoclonal antibodies in specificity and reproducibility .

How does MTK2 perform across different species samples?

MTK2 was developed against human c-kit, so cross-reactivity with other species must be experimentally validated:

When working with non-human samples, include appropriate positive controls and consider sequence alignment analysis to predict potential cross-reactivity.

Can MTK2 antibody be used to investigate c-kit receptor internalization?

To study c-kit internalization and trafficking:

• Label surface c-kit at 4°C with MTK2 antibody

• Stimulate with SCF and incubate at 37°C for various time points (5-60 minutes)

• Fix cells and analyze by confocal microscopy to track internalization

• Counterstain with markers for endocytic compartments (early endosomes, late endosomes, lysosomes)

• Quantify colocalization over time to map trafficking routes

Alternative approaches include:

• Using directly conjugated MTK2 with pH-sensitive fluorophores

• Surface biotinylation followed by MTK2 immunoprecipitation to quantify internalization rates

• Flow cytometry-based internalization assays comparing surface versus total c-kit staining

These approaches can reveal how mutations, drug treatments, or interacting proteins affect c-kit endocytosis and degradation.

How should I interpret contradictory results between MTK2 binding and functional c-kit assays?

When facing discrepancies between MTK2 binding and functional assays:

• Epitope accessibility: MTK2 binds a specific epitope that might not correlate with functional status; it doesn't inhibit SCF-induced activation unlike MTK1

• Receptor conformations: c-kit exists in different conformational states that may affect epitope exposure

• Threshold effects: Protein detection thresholds may differ from functional thresholds

• Post-translational modifications: Different PTMs may affect antibody binding without altering function or vice versa

• Isoform differences: Alternative splicing may create variants with different functional profiles

• Technical variables: Different sensitivities between binding and functional assays

When encountering contradictions, use complementary approaches: combine MTK1 (which affects function) with MTK2 (which doesn't) to gain comprehensive understanding of c-kit status in your experimental system .

How might MTK2 be used in conjunction with CRISPR-edited cell lines?

MTK2 antibody can be effectively combined with CRISPR technology:

• Validation studies: Use CRISPR to knockout c-kit in cells to confirm MTK2 specificity

• Domain mapping: Create c-kit variants with specific domain deletions to map MTK2's epitope

• Structure-function studies: Introduce point mutations and correlate with MTK2 binding and function

• Reporter systems: Use CRISPR to tag endogenous c-kit with fluorescent proteins and correlate with MTK2 staining

• Therapeutic research: Study MTK2 binding to engineered c-kit variants relevant to disease

This combination of technologies enables precise delineation of c-kit biology and potentially identifies novel therapeutic approaches for c-kit-related diseases.

What role might MTK2 play in developing CAR-T cell therapies targeting c-kit?

While MTK2 itself is likely not suitable for CAR-T development (as it doesn't inhibit function), the antibody can contribute to c-kit-targeted immunotherapies:

• Epitope mapping: Identify non-inhibitory binding sites that could be targeted by CAR-T cells

• Screening tool: Evaluate c-kit expression in patient samples before CAR-T treatment

• Companion diagnostics: Monitor c-kit levels during treatment

• Affinity optimization: Use as a control when developing high-affinity CAR constructs

• Binding domain engineering: Sequence information from MTK2 could inform CAR design

Research suggests that carefully selected antibody-derived binding domains are crucial for CAR-T efficacy against solid tumors .

How could MTK2 contribute to understanding c-kit's role in disease models?

MTK2 can facilitate research in various disease models where c-kit plays important roles:

• Cancer research: Detection of c-kit in gastrointestinal stromal tumors, melanoma, and leukemias

• Stem cell biology: Tracking c-kit+ cardiac progenitor cells in heart disease models

• Hematopoietic disorders: Analyzing abnormal c-kit expression or mutations in blood disorders

• Developmental biology: Studying c-kit in melanocyte or germ cell development

• Mast cell disorders: Investigating systemic mastocytosis where c-kit is constitutively active

The non-inhibitory nature of MTK2 makes it particularly valuable for detection studies where preserving c-kit function is important , enabling correlations between expression patterns and disease progression.